Clinical trials: Multi-System-Atrophy
Multiple System Atrophy
Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy
This study is based on positive results in open label trial of mesenchymal stem cells therapy in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT00911365
- Testing
- autologous mesenchymal stem cells, normal saline
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Multiple Sclerosis
Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis
The hypothesis is that 95% pure EGCG can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons…
- Trial name
- NCT02011451
- Testing
- 95% Pure ECGC capsules 200mg
- Where
- United States
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Parkinson Disease, Multiple System Atrophy
Synuclein-One Study
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
- Trial name
- NCT04700722
- Testing
- Skin Biopsy
- Where
- 23 sites in United States
- Volunteers
- 428 people
- Sponsor
- CND Life Sciences
Multiple System Atrophy
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Trial name
- NCT06868628
- Testing
- Foralumab Nasal
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tiziana Life Sciences LTD
Atypical Parkinsonism, Dementia With Lewy Bodies
Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
The goal of this retrospective observational study is to describe the efficacy of focused ultrasound ventral-intermediate nucleus thalamotomy in patients with atypical parkinsonism.
- Conditions
- Atypical Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy, MSA
- Trial name
- FUSAP (NCT06204575)
- Testing
- Data collection
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Rambam Health Care Campus
Frailty, Fall
Validation and Application of a Multi-dimentional Frailty Assessment Tool-Cohort Intervention and Follow up
We aim to (1) use a multifaceted, frailty assessment model. (2) use randomized controlled trials to deal with and intervene with cross-field, multi-faceted and intelligent remote management strategies for the elderly with…
- Conditions
- Frailty, Fall, Sarcopenia
- Trial name
- NCT05731167
- Testing
- Multidomain frailty prevention method, Regular follow up
- Where
- Taiwan
- Volunteers
- 216 people
- Sponsor
- National Taiwan University Hospital
Ataxia, Spinocerebellar Ataxias
Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia
The aim of the study is to evaluate the effects on motor and cognitive performance of transcranial alternating current stimulation (tACS) compared to transcranial direct current stimulation (tDCS) and placebo stimulation (sham)…
- Conditions
- Ataxia, Spinocerebellar Ataxias, Multiple System Atrophy, Ataxia With Oculomotor Apraxia
- Trial name
- SCAtACS (NCT05621200)
- Testing
- Transcranial stimulation over the cerebellar hemispheres
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Parkinson Disease, MSA - Multiple System Atrophy
Manipulating and Optimising Brain Rhythms for Enhancement of Sleep
Treatment of sleep disturbances is mainly attempted through drug administration. However, certain drugs are associated with unwanted side effects or residual effects upon awakening (e.g.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Chronic Pain, Epilepsy
- Trial name
- MORPHEUS (NCT05011773)
- Testing
- Deep brain stimulation
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University of Oxford
Spinal Muscular Atrophy
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)
The primary objective is to examine the clinical efficacy of multiple doses of nusinersen (ISIS 396443) administered intrathecally to participants with Infantile-Onset Spinal Muscular Atrophy (SMA).
- Trial name
- NCT01839656
- Testing
- nusinersen
- Where
- 4 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Biogen
Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
- Trial name
- NCT05864365
- Testing
- ATH434
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alterity Therapeutics
Fragile X Syndrome, Angelman Syndrome
Parent and Infant Inter(X)Action Intervention (PIXI)
The objective is to develop and test, through an iterative process, an intervention to address and support the development of infants with a confirmed diagnosis of a neurogenetic disorder with associated developmental delays or…
- Conditions
- Fragile X Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Dup15Q Syndrome
- Trial name
- NCT03836300
- Testing
- Parent-Infant Inter(X)action Intervention (PIXI)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- RTI International
Multiple System Atrophy
Lithium in Multiple System Atrophy
The purpose of this study is to determine safety and tolerability of the treatment with lithium in Multiple System Atrophy. Moreover, clinical symptoms, neuronal loss, quality of life and depressive symptoms, will be considered…
- Trial name
- LAMU (NCT00997672)
- Testing
- Lithium Carbonate
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Federico II University
α-synucleinopathy, Parkinson's Disease (PD)
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
The main objective of this study is to establish a standardized method for [18F] - FD17 PET imaging in α-synucleinopathy patients, and to analyze its physiological distribution in healthy individuals as well as its pathological…
- Conditions
- α-synucleinopathy, Parkinson's Disease (PD), Multiple System Atrophy, Rapid Eye Movement Sleep Behavior Disorder
- Trial name
- NCT06738862
- Testing
- PET
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Cerebral Palsy, Caregiver Burden
Awareness Levels of Caregivers of Disabled Children
Disability-or apology; It is the inability or incompleteness of individuals to fulfill their roles in life, such as age, gender, culture, social and psychological factors, due to their inadequacies.
- Conditions
- Cerebral Palsy, Caregiver Burden, Disabilities Multiple, Muscular Dystrophy
- Trial name
- caregivers (NCT05228405)
- Testing
- All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Spinal Muscular Atrophy
Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease caused by a mutation of exon 7, in 95% of cases, encoding the gene for the motor neuron survival protein called SMN1 (Survival Motor Neuron) located on chromosome…
- Trial name
- NUSI-AD-5qSM (NCT04576494)
- Testing
- Monthly assessments of functional motor abilities by a trained therapist, Nusinersen
- Where
- France
- Volunteers
- 4 people
- Sponsor
- CHU de Reims
Multiple System Atrophy
High-Altitude Neurodegeneration Cohort (HANC) Study
Chronic physiological hypoxia has been implicated in the pathogenesis of multiple system atrophy (MSA), a fatal neurodegenerative disorder of unknown etiology.
- Trial name
- HANC (NCT07657520)
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- West China Hospital
Diabetic Retinopathy, Retinal Vein Occlusion
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma.
- Conditions
- Diabetic Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion, Central Serous Chorioretinopathy
- Trial name
- NCT04723160
- Testing
- Software assisted imaging diagnosis
- Where
- 5 sites in China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Visionary Intelligence Ltd.
Spinal Muscular Atrophy Type 3
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.
- Trial name
- NCT06421831
- Testing
- GC101
- Where
- China
- Volunteers
- 21 people
- Sponsor
- GeneCradle Inc
Multiple System Atrophy
Quality of Life of Caregivers and Patients Suffering From Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder that cause as other neurodegenerative diseases profound declines in functioning and thus, require caregiving for assistance with daily living.
- Trial name
- QUA2-AMS (NCT04965922)
- Testing
- Multimodal intervention
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group